Annual Drug Patent Expirations for CONTRAVE Contrave is a drug marketed by Nalpropion and is included in one NDA. It […]
Source
New patent expiration for Nalpropion drug CONTRAVE Read Post »
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […]
Source
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »
This chart shows the pharmaceutical companies with the most pellets dosed drugs. For a different perspective, see the most popular […]
Source
Which pharmaceutical companies have the most pellets dosed drugs? Read Post »
The Rise of Clean Label and Natural Ingredients The trend towards organic and natural products has been growing steadily over the years. Consumers are increasingly looking for products that are free from synthetic ingredients and have a cleaner label. …
Excipient-Free Alternatives: What Are the Options? Read Post »
Annual Drug Patent Expirations for QLOSI Qlosi is a drug marketed by Orasis Pharms and is included in one NDA. […]
Source
Annual Drug Patent Expirations for TLANDO Tlando is a drug marketed by Verity and is included in one NDA. It […]
Source
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […]
Source
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »
This chart shows the companies which have received the most New Combination exclusivities in the past five years. New Combinations […]
Source
Pharmaceutical companies with the most ‘New Combination’ drugs Read Post »
Transitioning to a new Contract Development and Manufacturing Organization (CDMO) can be a complex and challenging process. However, by following […]
Source
Genetic engineering has been a crucial component of biotechnology for decades, and its future holds immense promise. From gene therapy
The Future of Genetic Engineering: Biotechnology’s Role Explained Read Post »
Get new actionable insights and updates from BiotechBlog
